AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
AbbVie's FY2025 10-K confirms the Humira biosimilar cliff is now a tailwind story, not a headwind. Skyrizi+Rinvoq = 42% of total revenue and growing. Forward P/E 14.4x on .12 EPS is attractive for a f...